Julie Dubourg
8PUBLICATIONS
3CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Dec 05, 2023
Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction-associated steatotic liver disease.Stephen A Harrison, Julie Dubourg, Maddie Knott
|Mar 09, 2023
Challenges and opportunities in NASH drug development.Stephen A Harrison, Alina M Allen, Julie Dubourg
|Jan 05, 2022
Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.Caroline Reilhac, Julie Dubourg, Carole Thang
|Dec 06, 2021
Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.Julie Dubourg, Pascale Fouqueray, Damien Quinslot
|Feb 12, 2021
Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.Julie Dubourg, Pascale Fouqueray, Carole Thang
|Dec 04, 2020
Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial.Julie Dubourg, Kohjiro Ueki, Jean-Marie Grouin
Pageof 2
